Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Syros Pharmaceuticals (SYRS)

Syros Pharmaceuticals (SYRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023 Business Wire - Wed May 3, 2023

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host...

SYRS : 5.03 (+0.60%)
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Tue May 2, 2023

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted...

SYRS : 5.03 (+0.60%)
Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update Business Wire - Thu Mar 2, 2023

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for...

SYRS : 5.03 (+0.60%)
Syros to Participate in Upcoming Investor Conferences in March Business Wire - Tue Feb 28, 2023

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive...

SYRS : 5.03 (+0.60%)
Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023 Business Wire - Thu Feb 23, 2023

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host...

SYRS : 5.03 (+0.60%)
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Thu Feb 9, 2023

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted...

SYRS : 5.03 (+0.60%)
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome Business Wire - Thu Jan 26, 2023

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the United...

SYRS : 5.03 (+0.60%)
Syros Announces Clinical Updates and 2023 Strategic Priorities Business Wire - Mon Jan 9, 2023

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in advancing new standards of care for the frontline treatment of hematologic malignancies, today provided an update on its clinical development programs and...

SYRS : 5.03 (+0.60%)
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Fri Dec 23, 2022

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 14,200...

SYRS : 5.03 (+0.60%)
Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS Business Wire - Mon Dec 12, 2022

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced a peer-reviewed publication of results from its completed biomarker-directed...

SYRS : 5.03 (+0.60%)

Barchart Exclusives

3 Standout Stocks to Buy for Q3 2024 Barchart - 1 hour ago
As we enter the third quarter of 2024, here are three promising stocks investors could consider buying. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot